We claim: DEAV2003/0020 Dr. WI

1. A compound of formula I:



I

wherein

Ring A is (C_3-C_8)-cycloalkanediyl or (C_3-C_8)-cycloalkenediyl, wherein one or more carbon atoms in said (C_3-C_8)-cycloalkane- and (C_3-C_8)-cycloalkenediyl groups may be replaced by oxygen atoms;

R1, R2 are each independently H, (C_1-C_6)-alkyl, (C_3-C_8)-cycloalkyl or (C_6-C_{10})-aryl;

R3 is (C_3-C_6)-cycloalkyl or (C_1-C_{12})-alkyl, each of which is optionally substituted by (C_6-C_{10})-aryl, (C_5-C_6)-heteroaryl or (C_3-C_6)-cycloalkyl, and wherein said (C_6-C_{10})-aryl, (C_5-C_6)-heteroaryl and (C_3-C_6)-cycloalkyl substituents are themselves optionally substituted by (C_1-C_6)-alkyl, (C_1-C_6)-alkoxy, Cl, Br, I, CO-(C_1-C_6)-alkyl, CO-O(C_1-C_6)-alkyl, CO-NH(C_1-C_6)-alkyl or CO-N$((C_1-C_6)$-alkyl$)_2$;

X is (C_1-C_6)-alkanediyl, wherein one or more carbon atoms therein are optionally replaced by oxygen atoms;

Y_1 is CO or a bond;

Y_2 is NH or (C_1-C_{12})-alkanediyl wherein one or more carbon atoms therein are optionally replaced by oxygen atoms;

R4 is (C_1-C_8)-alkyl;

R5 is H or $(C_1$-$C_6)$-alkyl;

R6 is H;

and pharmaceutically acceptable salts thereof.

2. The compound of Claim 1 wherein:

Ring A is $(C_3$-$C_8)$-cycloalkane-1,3-diyl;

R1, R2 are each independently H, $(C_1$-$C_6)$-alkyl, $(C_3$-$C_8)$-cycloalkyl or $(C_6$-$C_{10})$-aryl;

R3 is $(C_1$-$C_{12})$-cycloalkyl optionally substituted by phenyl, wherein said phenyl substituent is optionally substituted by $(C_1$-$C_6)$-alkyl;

X is $(C_1$-$C_6)$-alkanediyl wherein one carbon atom therein is optionally replaced by an oxygen atom;

Y_1 is CO or a bond;

Y_2 is NH or $(C_1$-$C_6)$-alkanediyl wherein one carbon atom therein is optionally replaced by an oxygen atom;

R4 is $(C_1$-$C_8)$-alkyl;

R5 is H or $(C_1$-$C_6)$-alkyl; and

R6 is H.

3. The compound of Claim 2 wherein:

Ring A is cyclohexane-1,3-diyl;

R1, R2 are each independently H, (C_1-C_6)-alkyl, (C_3-C_8)-cycloalkyl or phenyl;

R3 is (C_1-C_{12})-alkyl optionally substituted by phenyl, wherein said phenyl substituent is optionally substituted by methyl;

X is (C_1-C_6)-alkanediyl wherein the carbon atom adjacent to ring A is optionally replaced by an oxygen atom;

Y_1 is CO or a bond;

Y_2 is NH or (C_1-C_6)-alkanediyl wherein one carbon atom therein is optionally replaced by an oxygen atom;

R4 is (C_1-C_8)-alkyl;

R5 is H or (C_1-C_4)-alkyl; and

R6 is H.

4. The compound of Claim 3 wherein:

Ring A is cyclohexane-1,3-diyl;

R1 is H;

R2 is (C_1-C_6)-alkyl, (C_3-C_8)-cycloalkyl or phenyl;

R3 is (C_1-C_8)-alkyl optionally substituted by phenyl, wherein said phenyl substitutent is optionally substituted by methyl;

X is CH_2CH_2O;

Y_1 is CO or a bond;

Y_2 is NH or $(C_1$-$C_4)$-alkanediyl;

R4 is $(C_1$-$C_6)$-alkyl;

R5 is H or $(C_1$-$C_4)$-alkyl; and

R6 is H.

5. The compound of Claim 4, wherein the bond X-ring A-Y_1 is cis-configured.

6. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and one or more compounds of Claim 1.

7. The pharmaceutical composition of Claim 6 further comprising at least one additional active ingredient.

8. The pharmaceutical composition of Claim 7 wherein said additional active ingredient has favorable effects on metabolic disturbances or disorders.

9. The pharmaceutical composition of Claim 7 wherein said additional active ingredient is an antidiabetic.

10. The pharmaceutical composition of Claim 7 wherein said additional active ingredient is a lipid modulator.

11. A method of treating disorders of fatty acid metabolism and glucose utilization comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Claim 1.

12. A method of treating disorders of insulin resistence comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Claim 1.

13. A method of treating diabetes mellitus including the prevention of the squelae associated therewith comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Claim 1.

14. A method of treating dyslipidemia and squelae associated therewith comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Claim 1.

15. A method of treating metabolic syndrome and conditions associated therewith comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Claim 1.

16. A method of treating disorders of fatty acid metabolism and glucose utilization comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Claim 1 in combination with at least one further active compound.

17. A method of treating disorders of insulin resistance comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Claim 1 in combination with at least one further active compound.